Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 191

1.

Screening for Neonatal Hyperbilirubinemia-First Do No Harm?

Grosse SD, Prosser LA, Botkin JR.

JAMA Pediatr. 2019 May 20. doi: 10.1001/jamapediatrics.2019.1194. [Epub ahead of print] No abstract available.

PMID:
31107538
2.

A practical guide to episode groupers for cost-of-illness analysis in health services research.

Peterson C, Grosse SD, Dunn A.

SAGE Open Med. 2019 Mar 29;7:2050312119840200. doi: 10.1177/2050312119840200. eCollection 2019. Review.

3.

Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time.

Grosse SD, Pike J, Soelaeman R, Tilford JM.

Pharmacoeconomics. 2019 Apr;37(4):461-473. doi: 10.1007/s40273-019-00782-9. Review.

PMID:
30953263
4.

Assessing the Hereditary Hemorrhagic Telangiectasia Algorithms in a Community-Based Patient Population.

Saparia T, Faughnan ME, Schneider JL, Almers LM, Chow N, Grosse SD, Kim H, Zaroff JG.

Perm J. 2019;23. pii: 18-145. doi: 10.7812/TPP/18-145.

5.

Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources.

Okolo AI, Soucie JM, Grosse SD, Roberson C, Janson IA, Allen M, Shapiro AD.

Haemophilia. 2019 Mar 29. doi: 10.1111/hae.13734. [Epub ahead of print]

PMID:
30924993
6.

Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada.

Karaceper MD, Khangura SD, Wilson K, Coyle D, Brownell M, Davies C, Dodds L, Feigenbaum A, Fell DB, Grosse SD, Guttmann A, Hawken S, Hayeems RZ, Kronick JB, Laberge AM, Little J, Mhanni A, Mitchell JJ, Nakhla M, Potter M, Prasad C, Rockman-Greenberg C, Sparkes R, Stockler S, Ueda K, Vallance H, Wilson BJ, Chakraborty P, Potter BK; Canadian Inherited Metabolic Diseases Research Network (CIMDRN).

Orphanet J Rare Dis. 2019 Mar 22;14(1):70. doi: 10.1186/s13023-019-1001-0.

7.

Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018.

Glidewell J, Grosse SD, Riehle-Colarusso T, Pinto N, Hudson J, Daskalov R, Gaviglio A, Darby E, Singh S, Sontag M.

MMWR Morb Mortal Wkly Rep. 2019 Feb 8;68(5):107-111. doi: 10.15585/mmwr.mm6805a3.

8.

Cystic Fibrosis And Ivacaftor Use: The Authors Reply.

Feng LB, Grosse SD, Sawicki GS.

Health Aff (Millwood). 2019 Feb;38(2):328. doi: 10.1377/hlthaff.2018.05268. No abstract available.

PMID:
30715990
9.

US State-Level Infertility Insurance Mandates and Health Plan Expenditures on Infertility Treatments.

Boulet SL, Kawwass J, Session D, Jamieson DJ, Kissin DM, Grosse SD.

Matern Child Health J. 2019 May;23(5):623-632. doi: 10.1007/s10995-018-2675-y.

PMID:
30600516
10.

Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations.

Grosse SD, Krueger KV, Pike J.

J Med Econ. 2018 Nov 15:1-8. doi: 10.1080/13696998.2018.1542520. [Epub ahead of print] Erratum in: J Med Econ. 2019 Mar 1;:1.

PMID:
30384792
11.

Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016.

Grosse SD, Do TQN, Vu M, Feng LB, Berry JG, Sawicki GS.

Pediatr Pulmonol. 2018 Dec;53(12):1611-1618. doi: 10.1002/ppul.24178. Epub 2018 Oct 31.

PMID:
30381911
12.

Adherence to Recommended Care Guidelines in the Treatment of Preschool-Age Medicaid-Enrolled Children With a Diagnosis of ADHD.

Moran A, Serban N, Danielson ML, Grosse SD, Cuffe SP.

Psychiatr Serv. 2019 Jan 1;70(1):26-34. doi: 10.1176/appi.ps.201800204. Epub 2018 Oct 30.

PMID:
30373494
13.

What Contribution Did Economic Evidence Make to the Adoption of Universal Newborn Hearing Screening Policies in the United States?

Grosse SD, Mason CA, Gaffney M, Thomson V, White KR.

Int J Neonatal Screen. 2018;4(3):25. doi: 10.3390/ijns4030025. Epub 2018 Jul 20.

14.

Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease.

Prosser LA, Lam KK, Grosse SD, Casale M, Kemper AR.

MDM Policy Pract. 2018 Jan-Jun;3(1). doi: 10.1177/2381468318763814. Epub 2018 Apr 18.

15.

Genomic sequencing in acutely ill infants: what will it take to demonstrate clinical value?

Grosse SD, Farnaes L.

Genet Med. 2019 Feb;21(2):269-271. doi: 10.1038/s41436-018-0124-3. Epub 2018 Aug 13. No abstract available.

PMID:
30100610
16.

Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.

Pike J, Grosse SD.

Appl Health Econ Health Policy. 2018 Dec;16(6):765-778. doi: 10.1007/s40258-018-0416-4. Review.

17.

Is universal tumor testing for Lynch syndrome cost-effective? It depends!

Grosse SD.

Genet Med. 2019 Jan;21(1):252-253. doi: 10.1038/s41436-018-0025-5. Epub 2018 May 15. No abstract available.

18.

Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.

Feng LB, Grosse SD, Green RF, Fink AK, Sawicki GS.

Health Aff (Millwood). 2018 May;37(5):773-779. doi: 10.1377/hlthaff.2017.1554.

19.

Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015.

Leung J, Dollard SC, Grosse SD, Chung W, Do T, Patel M, Lanzieri TM.

Clin Ther. 2018 Mar;40(3):430-439.e1. doi: 10.1016/j.clinthera.2018.01.006. Epub 2018 Feb 4.

20.

Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review.

Grosse SD, Peterson C, Abouk R, Glidewell J, Oster ME.

Int J Neonatal Screen. 2017;3(4):34. doi: 10.3390/ijns3040034. Epub 2017 Dec 14.

Supplemental Content

Loading ...
Support Center